PL4554562T3 - Kompozycje olanzapiny i sposoby zastosowania - Google Patents

Kompozycje olanzapiny i sposoby zastosowania

Info

Publication number
PL4554562T3
PL4554562T3 PL24700866.7T PL24700866T PL4554562T3 PL 4554562 T3 PL4554562 T3 PL 4554562T3 PL 24700866 T PL24700866 T PL 24700866T PL 4554562 T3 PL4554562 T3 PL 4554562T3
Authority
PL
Poland
Prior art keywords
methods
olanzapine compositions
olanzapine
compositions
Prior art date
Application number
PL24700866.7T
Other languages
English (en)
Inventor
Mélodie CARLUER
Maria Ferrand
Irina CHERNIAKOV
Anna Elgart VALITSKY
Original Assignee
Medincell Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell Sa filed Critical Medincell Sa
Publication of PL4554562T3 publication Critical patent/PL4554562T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL24700866.7T 2023-01-10 2024-01-10 Kompozycje olanzapiny i sposoby zastosowania PL4554562T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363479267P 2023-01-10 2023-01-10
US202363516283P 2023-07-28 2023-07-28
PCT/EP2024/050429 WO2024149778A1 (en) 2023-01-10 2024-01-10 Olanzapine compositions and methods of use

Publications (1)

Publication Number Publication Date
PL4554562T3 true PL4554562T3 (pl) 2026-02-09

Family

ID=89661117

Family Applications (1)

Application Number Title Priority Date Filing Date
PL24700866.7T PL4554562T3 (pl) 2023-01-10 2024-01-10 Kompozycje olanzapiny i sposoby zastosowania

Country Status (21)

Country Link
US (3) US20260216206A1 (pl)
EP (2) EP4691491A3 (pl)
JP (1) JP2026501805A (pl)
KR (1) KR20250129781A (pl)
AU (1) AU2024208071A1 (pl)
CA (1) CA3266264A1 (pl)
CL (1) CL2025002025A1 (pl)
DK (1) DK4554562T3 (pl)
ES (1) ES3055278T3 (pl)
FI (1) FI4554562T3 (pl)
HR (1) HRP20251423T1 (pl)
IL (1) IL321134A (pl)
LT (1) LT4554562T (pl)
MX (1) MX2025008012A (pl)
PE (1) PE20252752A1 (pl)
PL (1) PL4554562T3 (pl)
PT (1) PT4554562T (pl)
RS (1) RS67477B1 (pl)
SI (1) SI4554562T1 (pl)
SM (1) SMT202500442T1 (pl)
WO (1) WO2024149778A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026003357A1 (en) 2024-06-28 2026-01-02 Teva Pharmaceuticals International Gmbh Medicament delivery kit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
MY165655A (en) 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
LT3655038T (lt) * 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija

Also Published As

Publication number Publication date
KR20250129781A (ko) 2025-08-29
ES3055278T3 (en) 2026-02-10
CL2025002025A1 (es) 2025-11-07
CA3266264A1 (en) 2024-07-18
EP4691491A3 (en) 2026-03-04
DK4554562T3 (da) 2025-12-01
RS67477B1 (sr) 2025-12-31
SI4554562T1 (sl) 2026-01-30
HRP20251423T1 (hr) 2025-12-19
US12220418B2 (en) 2025-02-11
PE20252752A1 (es) 2025-12-05
MX2025008012A (es) 2025-08-01
US20260216206A1 (en) 2026-07-30
EP4554562A1 (en) 2025-05-21
SMT202500442T1 (it) 2026-01-12
AU2024208071A1 (en) 2025-06-12
CN120569188A (zh) 2025-08-29
PT4554562T (pt) 2025-11-25
FI4554562T3 (fi) 2025-11-25
WO2024149778A1 (en) 2024-07-18
US20240238308A1 (en) 2024-07-18
EP4691491A2 (en) 2026-02-11
EP4554562B1 (en) 2025-09-10
IL321134A (en) 2025-07-01
LT4554562T (lt) 2025-12-10
US20240325408A1 (en) 2024-10-03
JP2026501805A (ja) 2026-01-16

Similar Documents

Publication Publication Date Title
IL309073A (en) Enantiomeric entactogen compounds and methods of their use.
IL308041A (en) Collagen compositions and methods of using them
HUE072193T2 (hu) Antitest kompozíciók és eljárások azok felhasználásához
IL316619A (en) PI3Kα inhibitors and methods of using them
IL314320A (en) Compounds and methods of use
IL315862A (en) Angiotensinogen modulators and methods of using them
PL4090332T3 (pl) Kompozycje podstawionych pirazolopirymidyn i ich zastosowania
GB2622995B (en) CAS13-based compositions and methods of use thereof
IL312928A (en) Complement Factor B Modulating Preparations and Methods for Using Them
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
IL318393A (en) Azaquinazoline compounds and methods of use
IL321134A (en) Olanzapine compounds and methods of use
IL325628A (en) Coagulation factor xi modulators and methods of using them
IL314277A (en) Anti-B7-H3 compounds and methods of use
IL314226A (en) Designed cytokine compositions and methods of use
IL314293A (en) Olanzapine, its compounds and methods of using it
GB202119051D0 (en) Wingsail and method of use
IL311518A (en) Preparations that modulate perkalkerine and methods of using them
IL312205A (en) Coxsackievirus B compounds and methods of using them
IL311037A (en) Lactoferrin preparations and methods of use
IL326294A (en) Apilimod compositions and methods of use
GB202313643D0 (en) Serping1-sarna compositions and methods of use
GB202310868D0 (en) compositions and methods of use
IL325884A (en) Gal475 compositions and methods of use thereof
GB202405768D0 (en) Compositions and uses of oligo-chromopeptides and methods of making